İleri Yaş Hastalarda Meme Kanseri
Özet
Dünya genelinde en sık görülen kanser olan meme kanseri yaşam beklentisinin arttığı günümüzde yaşlılık ve meme kanseri birlikteliğine zemin hazırlamaktadır. İleri yaş kanser hastası tedavisi ile sadece kanserle mücadele değil aynı zamanda komorbiditelerle de mücadele etmek gerekmektedir. Uygulanacak tedavilerin seçimi yaş, kullanılan ilaçlar, eşlik eden hastalıklar, performans ve yaşam beklentisinden etkilenmektedir. Çalışmalarda yaşlı hastalara yeterince yer verilmemesi ve belki de tedavi seçimindeki çekimser tutum, klinik uygulama kılavuzlarında bu hasta gurubunun uygun şekilde ele alınamamasına neden olmaktadır. Bu da tedavinin bazen tecrübelere dayalı olarak belirlenmesi ile sonuçlanmaktadır. Günümüzde yaşlılık, meme ve axilla cerrahisi için bir engel teşkil etmemektedir. Cerrahi öncesinde ve sonrasında uygulanacak kemoterapi ve hedefe yönelik tedaviler de yakın takip ile sorunsuz uygulanabilmektedir. Radyoterapi de yine uygun hasta seçimi ile bazen yerini endokrin tedaviye bırakabilmektedir.
Referanslar
Alterovitz SS, Mendelsohn GA. Relationship goals of middle-aged, young-old, and old-old Internet daters: an analysis of online personal ads. J Aging Stud. 2013 Apr;27(2):159-65. doi: 10.1016/j.jaging.2012.12.006. Epub 2013 Feb 9.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/CAAC.21708
World Health Organization (WHO). Cancer. https://gco.iarc.fr/en/ (Erişim tarihi: 21.02.2025)
Shachar SS, Hurria A, Muss HB. Breast cancer in women older than 80 years. J Oncol Pract. 2016;12(2):123–132. doi: 10.1200/JOP.2015.010207
Morgan JL, Walters SJ, Collins K, et al. What influences healthcare professionals’ treatment preferences for older women with operable breast cancer? An application of the discrete choice experiment. Eur J Surg Oncol. 2017;43(7):1282–1287. doi: 10.1016/J.EJSO.2017.01.012
Morgan JL, George J, Holmes G, et al. Breast cancer surgery in older women: outcomes of the Bridging Age Gap in Breast Cancer study. Br J Surg. 2020;107(11):1468–1479. doi: 10.1002/BJS.11617
Soyder A, Ozbaş S, Koçak S. Locoregional Recurrence and Survival Rates after Breast-Conserving Surgery and Hormonal Therapy in 70-Year-Old or Older Patients with Stage I or IIA Breast Carcinoma. Breast Care (Basel). 2013 May;8(2):134-7. doi: 10.1159/000350776.
Martelli G, Miceli G, Costa A, et al. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: 15-year results of a prospective study. Cancer. 2008;112:481–488. doi: 10.1002/cncr.23213.
Christian N, Heelan Gladden A, Friedman C, et al. Increasing omission of radiation therapy and sentinel node biopsy in elderly patients with early stage, hormone-positive breast cancer. Breast J. 2020;26(2):133–138. doi: 10.1111/TBJ.13483
Liang S, Hallet J, Simpson JS, et al. Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: a systematic review and meta-analysis. J Geriatr Oncol. 2017;8(2):140–147. doi: 10.1016/J.JGO.2016.12.003
Poodt IGM, Schipper RJ, Vugts G, et al. The rationale for and long-term outcome of incomplete axillary staging in elderly women with primary breast cancer. Eur J Surg Oncol. 2018 Nov;44(11):1714-1719. doi: 10.1016/j.ejso.2018.07.005. Epub 2018 Jul 27.
Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470.
Galimberti V, Cole BF, Viale G, et al. International Breast Cancer Study Group Trial 23-01. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018 Oct;19(10):1385-1393. doi: 10.1016/S1470-2045(18)30380-2. Epub 2018 Sep 5.
Corso G, Magnoni F, Montagna G, et al. Long-term outcome and axillary recurrence in elderly women (≥70 years) with breast cancer: 10-years follow-up from a matched cohort study. Eur J Surg Oncol. 2021 Jul;47(7):1593-1600. doi: 10.1016/j.ejso.2021.02.027. Epub 2021 Mar 3.
Abdel-Razeq H, Abu Rous F, Abuhijla F, et al. Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects. Clin Interv Aging. 2022 Sep 28;17:1445-1460. doi: 10.2147/CIA.S365497.
Derks MGM, van de Velde CJH, Giardiello D, et al. Impact of comorbidities and age on cause-specific mortality in postmenopausal patients with breast cancer. Oncologist. 2019;24(7):e467-e474. doi: 10.1634/theoncologist.2018-0010
Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24(18):2750–2756. doi: 10.1200/JCO.2005.02.3028
Tamirisa N, Lin H, Shen Y, et al. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer. JAMA Oncol. 2020 Oct 1;6(10):1548-1554. doi: 10.1001/jamaoncol.2020.2388.
Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007 Sep 1;25(25):3808-15. doi: 10.1200/JCO.2006.10.4976. Epub 2007 Jul 30.
Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009 Mar 10;27(8):1177-83. doi: 10.1200/JCO.2008.18.4028. Epub 2009 Feb 9.
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003 Jun 1;97(11):2869-79. doi: 10.1002/cncr.11407.
Brollo J, Curigliano G, Disalvatore D, et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev. 2013 Feb;39(1):44-50. doi: 10.1016/j.ctrv.2012.03.009. Epub 2012 Apr 27.
Fumoleau P, Roché H, Kerbrat P, et al. Adjuvant Study Group. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol. 2006 Jan;17(1):85-92. doi: 10.1093/annonc/mdj034. Epub 2005 Oct 26.
Mackey JR, Martin M, Pienkowski T, et al. TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan;14(1):72-80. doi: 10.1016/S1470-2045(12)70525-9. Epub 2012 Dec 12.
Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013 Nov 20;31(33):4222-8. doi: 10.1200/JCO.2013.48.7884. Epub 2013 Oct 14.
von Minckwitz G, Procter M, de Azambuja E, et al. APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. Erratum in: N Engl J Med. 2017 Aug 17;377(7):702. doi: 10.1056/NEJMx170011. Erratum in: N Engl J Med. 2018 Oct 18;379(16):1585.
von Minckwitz G, Huang CS, Mano MS, et al. KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017.
Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women over 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–977. doi: 10.1056/NEJMoa040587.
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–1241. doi: 10.1056/NEJMoa022152.
Mandish SF, Gaskins JT, Yusuf MB, et al. The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response. Acta Oncol. 2020 Oct;59(10):1210-1217. doi: 10.1080/0284186X.2020.1797161. Epub 2020 Jul 27.
Crystal JS, Rand J, Johnson J, et al. Adjuvant endocrine therapy is associated with improved overall survival in elderly hormone receptor-positive breast cancer patients. Breast Cancer Res Treat. 2020 Nov;184(1):63-74. doi: 10.1007/s10549-020-05823-y. Epub 2020 Aug 9.
Madigan LI, Dinh P, Graham JD. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines. Breast Cancer Res. 2020 Jul 20;22(1):77. doi: 10.1186/s13058-020-01314-6.
Aapro M, Monfardini S, Jirillo A, et al. Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treat Rev. 2009 Oct;35(6):503-8. doi: 10.1016/j.ctrv.2009.04.002. Epub 2009 Sep 16.
Carrick S, Parker S, Thornton CE, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009 Apr 15;2009(2):CD003372. doi: 10.1002/14651858.CD003372.pub3.
Freedman RA, Tolaney SM. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review. Breast Cancer Res Treat. 2018 Feb;167(3):607-614. doi: 10.1007/s10549-017-4560-6. Epub 2017 Nov 4.
